SCHEMBL2441972

SCHEMBL2441972

NC(=O)c1cc(N[C]=O)ccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.39
TSHR P16473 1/20 0.39
MC4R P32245 1/20 0.39
ADRA1A P35348 1/20 0.39
MC3R P41968 1/20 0.39
SCN10A Q9Y5Y9 4/20 0.39
TGFBR1 P36897 1/20 0.36
GSK3B P49841 4/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
MYC P01106 1/20 0.36
RAF1 P04049 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM6B O15054 1/20 0.34
TET3 O43151 1/20 0.34
KDM4A O75164 1/20 0.34
BBOX1 O75936 1/20 0.34
MAPT P10636 1/20 0.34
KDM5A P29375 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437937 0.84 KDM4E (0.52) SCN10AKDM4EALDH1A1KDM6BTET3
SCHEMBL2437319 0.79 ALDH1A1 (0.41) RAF1KDM4EALDH1A1MAPTANO1
SCHEMBL17076844 0.79 APP (0.43) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL2439859 0.79 NPC1 (0.43) TSHRALDH1A1MAPT
SCHEMBL28292635 0.77 SCN10A (0.44) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL20652765 0.76 ADORA3 (0.39) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL2441973 0.76 ADORA3 (0.39) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL2442535 0.75 SMYD3 (0.51) ANO1
SCHEMBL2440460 0.75 AR (0.44) RAF1ANO1
SCHEMBL2439973 0.75 RAB9A (0.47) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-05-03 US disclosed
US-8017612-B2 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2011-09-13 US disclosed
EP-2009004-A1 NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR Japan Tobacco, Inc. (JP) 2008-12-31 EP disclosed
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors JAPAN TOBACCO INC. (JP) 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081818-A1 therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors HAVCR2, AADAC, DNPEP ADORA3 1979/4885TSHR 3775/4885MC4R 4668/4885
US-20120107273-A1 NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR POLR1C, POLR2E, POLR2H ADORA3 4473/4885TSHR 4735/4885MC4R 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.